Advances in immunogenetic mechanisms of drug-induced liver injury
10.12092/j.issn.1009-2501.2025.08.016
- VernacularTitle:药物性肝损伤的免疫遗传学机制研究进展
- Author:
Xiangchang ZENG
1
;
Tai RAO
;
Lulu CHEN
;
Chaopeng LI
;
Guirong ZENG
;
Jun CHEN
;
Dongsheng OUYANG
Author Information
1. 中南大学湘雅医院临床药理研究所,长沙 410008,湖南;长沙都正生物科技股份有限公司,复杂基质样本生物分析湖南省重点实验室,长沙 410205,湖南;中南大学临床药理研究所,遗传药理学湖南省重点实验室,长沙 410078,湖南;药物基因组应用技术教育部工程研究中心,长沙 410078,湖南;国家老年疾病临床医学研究中心,长沙 410008,湖南;深圳市第三人民医院,南方科技大学第二附属医院疑难重症肝病科,深圳 518055,广东
- Publication Type:Journal Article
- Keywords:
drug-induced liver injury;
human leu-kocyte antigen;
immunogenetics;
pharmacogenom-ics
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(8):1133-1146
- CountryChina
- Language:Chinese
-
Abstract:
Drug-induced liver injury(DILI)is one of the major challenges in drug development and clinical practice,and effective prevention and con-trol measures remain lacking.Research has shown that DILI is primarily mediated by immune respons-es.Human leukocyte antigen(HLA)alleles are cur-rently the strongest genetic factors reported to be associated with DILI.Due to the low positive predic-tive value of HLA alleles,preemptive HLA genetic screening has limited clinical utility in preventing DILI.However,its high negative predictive value makes it valuable for DILI diagnosis and causality assessment.In recent years,polymorphisms in im-mune-related genes-such as those involved in anti-gen processing and presentation pathways,T-cell receptors,immunostimulatory molecules,and cyto-kines-have been found to be associated with DILI.Future studies combining these genes with HLA analysis may provide deeper mechanistic insights into DILI and facilitate their translational applica-tion in clinical practice,ultimately improving drug safety.
